Thanks for the opportunity. If we see that the first half strong action in the revenue, that is 26% growth, and we already have incremental four molecules in the commercial phase, then we see that the CP 6, CP 7, 130 kiloliter already installed. Considering Unit-III, that's a Rs. 350 Cr plus Rs. 100 Cr of CAPEX; can we see the similar rate revenue growth for the next six months and for FY27?
Questions across 4 calls
Ankush Mahajan
Firm not listed in source transcripts
Anthem Biosciences Limited
Lupin Limited
Thanks for the opportunity. Ma'am, we have U.S. revenue in the range of $211 million now. So, this run rate, could you give me some sense of what kind of a run rate that we can expect in upcoming quarters? Because you already have inched to $211 million from $181 million.
For the upcoming quarters.
Aurobindo Pharma Limited
Good morning, Sir. Sir, my question is related to the injectables. Taking run rate of the gRevlimid, [are] the other injectables either flat or showing some declining [trend]?. I’m just trying to understand how is the price erosion in the base injectable business if I deducted the gRevlimid part?
Okay, Sir. Thank you.
Sir, my question is related to the Eugia-II. What kind of a price erosion was in the existing products? And, Sir, what is the strategy for the new launches from the Eugia-II now?
Yes, Sir. Yes, Sir. So, what is the price erosion in the existing products? And what is the strategy for the new launches from the Eugia-II?